Spyre Therapeutics (NASDAQ:SYRE) Earns Buy Rating from BTIG Research

Spyre Therapeutics (NASDAQ:SYRE)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a report released on Friday,Benzinga reports. They presently have a $70.00 price target on the stock. BTIG Research’s price objective suggests a potential upside of 62.00% from the stock’s current price.

A number of other analysts also recently commented on SYRE. Mizuho upgraded Spyre Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Wall Street Zen raised Spyre Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Citigroup assumed coverage on Spyre Therapeutics in a research report on Wednesday, December 17th. They issued a “buy” rating and a $64.00 price objective on the stock. JonesTrading raised shares of Spyre Therapeutics from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a report on Monday, December 1st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Spyre Therapeutics in a research note on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $53.44.

Spyre Therapeutics Price Performance

Shares of SYRE opened at $43.21 on Friday. The business’s 50 day simple moving average is $33.40 and its 200-day simple moving average is $25.35. The stock has a market capitalization of $3.35 billion, a price-to-earnings ratio of -20.77 and a beta of 3.15. Spyre Therapeutics has a 1 year low of $10.91 and a 1 year high of $43.56.

Spyre Therapeutics (NASDAQ:SYRE) last released its earnings results on Thursday, February 26th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). On average, sell-side analysts expect that Spyre Therapeutics will post -4.46 earnings per share for the current year.

Insiders Place Their Bets

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $32.80, for a total transaction of $492,000.00. Following the completion of the transaction, the chief executive officer directly owned 657,540 shares in the company, valued at approximately $21,567,312. This represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold 45,000 shares of company stock worth $1,387,500 in the last ninety days. Corporate insiders own 15.43% of the company’s stock.

Institutional Trading of Spyre Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. RTW Investments LP raised its position in shares of Spyre Therapeutics by 15.2% during the 4th quarter. RTW Investments LP now owns 4,171,996 shares of the company’s stock worth $136,675,000 after purchasing an additional 550,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Spyre Therapeutics by 32.3% during the fourth quarter. Vanguard Group Inc. now owns 4,035,074 shares of the company’s stock valued at $132,189,000 after acquiring an additional 984,344 shares during the last quarter. Capital International Investors lifted its position in shares of Spyre Therapeutics by 46.0% in the fourth quarter. Capital International Investors now owns 3,492,541 shares of the company’s stock valued at $114,416,000 after acquiring an additional 1,100,000 shares in the last quarter. Perceptive Advisors LLC lifted its position in shares of Spyre Therapeutics by 149.6% in the fourth quarter. Perceptive Advisors LLC now owns 3,069,225 shares of the company’s stock valued at $100,548,000 after acquiring an additional 1,839,780 shares in the last quarter. Finally, Commodore Capital LP boosted its stake in shares of Spyre Therapeutics by 20.1% in the fourth quarter. Commodore Capital LP now owns 2,388,245 shares of the company’s stock worth $78,239,000 after acquiring an additional 400,161 shares during the last quarter. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics News Roundup

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and kept a $70 price target (roughly +62% upside vs. current levels), signaling strong buy-side conviction from a sell-side firm. BTIG Reaffirms Buy, $70 PT
• Positive Sentiment: Wells Fargo raised its price target to $50 and assigned an “overweight” rating, providing additional analyst support that likely helped lift the stock. Wells Fargo Raises PT to $50
• Positive Sentiment: Spyre reported a strong cash position — $757M in cash, equivalents and marketable securities as of 12/31/25 — and said that runway is expected into H2 2028, reducing near-term financing risk. The company also completed an offering in Oct 2025 and added a Chief Commercial Officer. Q4 & Corporate Update
• Positive Sentiment: Management reiterated an aggressive 2026 clinical cadence: up to six proof-of-concept readouts across the SKYLINE and SKYWAY Phase 2 programs (including Part A readouts starting in Q2 and multiple basket-study sub-readouts later in the year), which creates several near-term clinical catalysts. Clinical Readouts and Timeline
• Neutral Sentiment: Spyre announced presentations at the 21st ECCO Congress showcasing SPY003’s differentiated profile and preclinical combo data — supportive from a scientific/visibility standpoint but not an immediate financial catalyst. ECCO Presentations
• Negative Sentiment: Spyre missed the quarterly EPS consensus (reported -$0.70 vs. est. -$0.66), a modest miss that may temper sentiment for investors focused on near-term financials. Earnings Release

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.